Novartis

News

Novartis app could revolutionise ophthalmic clinical trials

Patients will be able to participate in clinical ophthalmology trials from home thanks to a groundbreaking digital app developed by Novartis.

News

Novartis and Pear to develop substance use digital therapeut...

Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea

News

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.

News

Novartis invests $100m in new malaria drugs

Concerns are mounting over resistance to artemisinin

News

Novartis buys neurology biotech AveXis for $8.7bn

Novartis has bought biotech AveXis for $8.7 billion, adding a potential gene therapy for the rare disease spinal muscular atrophy (SMA) to its pipeline.

News

GSK to pay $13bn for Novartis stake in OTC joint venture

GlaxoSmithKline is to buy out Novartis from their over-the-counter joint venture, and may sell its Horlicks business to fund the £9.2 billion ($13bn) acquisition.

Novartis app could revolutionise ophthalmic clinical trials

Novartis and Pear to develop substance use digital therapeut...

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis invests $100m in new malaria drugs

Novartis buys neurology biotech AveXis for $8.7bn

GSK to pay $13bn for Novartis stake in OTC joint venture

Dismay as FDA blocks Regenxbio's Hunter syndrome therapy

How to meet your physicians where they are online

Novartis

Editor's Picks